Special Phage Holdings wins NSW commercialisation award

Progen goes into Phase III and ChemGenex Phase II, Bionomics looks at anxiety, Clinuvel gets orphan designation and Avexa announces collaboration and good results.

NSW is running its annual BioFirst commercialisation awards again, offering cash and advice for local biotechs.

Diagnostic platform developer Medsaic has won the NSW government's inaugural BioFirst commercialisation award, at a ceremony on Monday evening.

With technology advancing so rapidly in many potential commercial areas of life science, patent attorneys, intellectual property (IP) and commercial lawyers, and lawmakers will face a number of challenges over the next 10 years, says Trevor Davies.

US antiviral therapeutics developer Nucleonics has claimed first blood in its attempt to have the Australian patent office revoke a key RNA interference (RNAi) gene-silencing patent owned jointly by CSIRO and Brisbane gene-therapy company Benitec (ASX:BLT).

You've run your experiments, got your results, and you've been mentally spending -- or at least licensing -- the proceeds of your bulging IP portfolio. But that may have been the easy part, writes Renate Krelle. Before you go any further, here's a checklist of some of the most common patenting pitfalls.

Victoria's new health privacy legislation would substantially impact upon the local biotechnology industry, a leading lawyer has predicted.

Changes to Australian patent laws from April 1 will make filing harder, but will also bring the country more into line with US and European patent laws.